Deutsche Bank assumed coverage on shares of Kura Oncology (NASDAQ:KURA) in a research report sent to investors on Thursday morning, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $28.00 price objective on the stock.
A number of other equities analysts have also weighed in on the company. BidaskClub lowered Xperi from a sell rating to a strong sell rating in a research report on Wednesday, June 19th. Citigroup set a $27.00 price target on PhaseBio Pharmaceuticals and gave the company a buy rating in a research report on Friday, May 24th. Zacks Investment Research lowered ExlService from a hold rating to a sell rating in a research report on Wednesday, July 10th. HC Wainwright set a $31.00 price target on Kura Oncology and gave the company a buy rating in a research report on Wednesday, May 8th. Finally, ValuEngine upgraded United Overseas Bank from a sell rating to a hold rating in a research report on Monday, June 17th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of Buy and a consensus price target of $28.00.
Shares of KURA stock opened at $19.05 on Thursday. The company’s 50-day moving average price is $18.89. Kura Oncology has a fifty-two week low of $10.20 and a fifty-two week high of $22.00. The company has a quick ratio of 13.80, a current ratio of 13.80 and a debt-to-equity ratio of 0.05.
Kura Oncology (NASDAQ:KURA) last announced its earnings results on Tuesday, May 7th. The company reported ($0.37) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.45) by $0.08. As a group, sell-side analysts predict that Kura Oncology will post -1.69 EPS for the current fiscal year.
In related news, insider Antonio Gualberto sold 18,000 shares of the stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $21.11, for a total value of $379,980.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 15.30% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. Great West Life Assurance Co. Can purchased a new stake in Kura Oncology in the 4th quarter worth about $62,000. BlackRock Inc. lifted its stake in Kura Oncology by 0.6% in the 4th quarter. BlackRock Inc. now owns 2,409,979 shares of the company’s stock worth $33,836,000 after acquiring an additional 13,842 shares in the last quarter. Fosun International Ltd lifted its stake in Kura Oncology by 49.8% in the 1st quarter. Fosun International Ltd now owns 305,958 shares of the company’s stock worth $4,972,000 after acquiring an additional 101,724 shares in the last quarter. Geode Capital Management LLC lifted its stake in Kura Oncology by 13.9% in the 4th quarter. Geode Capital Management LLC now owns 354,010 shares of the company’s stock worth $4,970,000 after acquiring an additional 43,205 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Kura Oncology by 8.2% in the 4th quarter. Bank of New York Mellon Corp now owns 121,473 shares of the company’s stock worth $1,706,000 after acquiring an additional 9,218 shares in the last quarter. 83.89% of the stock is owned by hedge funds and other institutional investors.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Read More: Are all No-Load Funds Equal?
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.